Consultation outcome

Classification of Nasonex Allergy Control Nasal Spray

From:
Medicines and Healthcare products Regulatory Agency
Published
21 November 2016
Last updated
10 July 2017 — See all updates
This consultation has concluded

Download the full outcome

Nasonex Allergy Control 0.05% Nasal Spray Public Assessment Report

PDF, 64.2 KB, 5 pages

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Nasonex Allergy Control 0.05% Nasal Spray from a prescription only medicine (POM) to a Pharmacy (P) medicine in the UK to treat the symptoms of hayfever (also called seasonal allergic rhinitis) and perennial allergic rhinitis for those 18 years and over, for a period of not more than 3 months.

See the public assessment report below for more information

Feedback received

Royal Pharmaceutical Society response

PDF, 44.3 KB, 2 pages

Royal College of Physicians response

PDF, 33.3 KB, 2 pages

Guild of Healthcare Pharmacists response

PDF, 13.6 KB, 2 pages

Freelance Regulatory Consultant response

PDF, 35.4 KB, 1 page

Detail of feedback received

Five responses were received. Four responses supported the proposal, one was unsure about the proposal. One of the responses was confidential.

See all the responses to this consultation.

Original consultation

Summary

We want to know what you think about our proposal to Nasonex Allergy Control Nasal Spray available without prescription.

This consultation ran from
to

Consultation description

We want to know what you think

  • Nasonex Allergy Control 0.05% Nasal Spray is used to treat the symptoms of hayfever (also called seasonal allergic rhinitis) and perennial allergic rhinitis (this occurs throughout the year).
  • Nasonex Allergy Control is only at the moment available on prescription.
  • We propose to make it available in pharmacies.
  • MHRA considers that this product can be available as a Pharmacy medicine.
  • We want to know what you think about this change.

Please tell us your views using the form at the end of the attached pdf.

The deadline for comments is 12 December 2016.

Documents

Nasonex Allergy Control 0.05% Nasal Spray Public Consultation Document

PDF, 7.72 MB, 19 pages

Response to Nasonex Allergy Control 0.05% Nasal Spray Public Consultation - Word version

MS Word Document, 253 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Published 21 November 2016
Last updated 10 July 2017 + show all updates

  1. Public assessment report and responses uploaded

  2. Added a Word version of the consultation response document.

  3. First published.

Related content